Understanding how myosin mutations cause heart disease
Modeling myosin mechanobiology towards understanding the mechanisms of hypertrophic cardiomyopathy
This study is looking at how certain changes in a heart protein can cause thickening of the heart muscle in people with hypertrophic cardiomyopathy (HCM), and it aims to find better, personalized treatments for those affected by this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11013826 on NIH RePORTER |
What this research studies
This research investigates how specific mutations in beta cardiac myosin lead to hypertrophic cardiomyopathy (HCM), a condition characterized by heart muscle thickening. By examining the molecular and cellular mechanisms involved, the study aims to clarify how these mutations affect heart cell behavior and contribute to disease symptoms. The research employs advanced techniques such as CRISPR gene editing and computational modeling to analyze the effects of these mutations in a controlled environment. Ultimately, the goal is to develop more personalized treatment options for patients with HCM.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with hypertrophic cardiomyopathy, particularly those with known mutations in beta cardiac myosin.
Not a fit: Patients without hypertrophic cardiomyopathy or those whose condition is unrelated to myosin mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and tailored therapies for patients suffering from hypertrophic cardiomyopathy.
How similar studies have performed: Previous research has shown promise in understanding cardiac diseases through similar molecular and computational approaches, indicating a potential for success in this area.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Vander Roest, Alison Schroer — University of Michigan at Ann Arbor
- Study coordinator: Vander Roest, Alison Schroer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.